Cha Charles, Fong Yuman, Jarnagin William R, Blumgart Leslie H, DeMatteo Ronald P
Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
J Am Coll Surg. 2003 Nov;197(5):753-8. doi: 10.1016/j.jamcollsurg.2003.07.003.
The majority of patients with hepatocellular carcinoma (HCC) who undergo complete tumor resection subsequently develop tumor recurrence. The objectives of this study were to determine the risk factors for recurrence of HCC after hepatectomy and to examine the outcomes once tumor recurrence occurs.
From February 1990 to May 2001 a total of 164 patients underwent liver resection for HCC at our institution and were prospectively followed. Time to recurrence and survival after recurrence were determined by Kaplan-Meier analysis. Patient, tumor, and treatment characteristics were tested for their prognostic significance by univariate and multivariate analysis using the logrank test and the Cox proportional hazards model, respectively.
The median patient age was 64 years (range 21 to 87 years) and 106 patients (65%) were male. After a median followup of 26 months, 90 patients (55%) have developed recurrent cancer. Among them, 75 patients (83%) had tumor detectable in the liver, which was the only site of disease in 67 (74%). In all, 15 patients (20%) had extrahepatic disease (7 lung, 4 peritoneum, 2 pancreas, 1 bone, and 1 brain). The median time to recurrence was 24 months (range 1 to 274 months). Predictors of recurrence on univariate analysis were tumor size greater than 5 cm, more than one tumor, cirrhosis, vascular invasion (microscopic or macroscopic), and tumor satellites. On multivariate analysis only tumor size greater than 5 cm (p = 0.04) and vascular invasion (p = 0.01) predicted recurrence. The median survival after recurrence was 11 months (range 0 to 60 months). Of the 90 patients who developed tumor recurrence 49 (67%) were able to undergo additional ablative or surgical therapy (33 embolization, 9 ethanol injection, and 14 re-resection). On multivariate analysis vascular invasion in the original tumor predicted poor survival after recurrence (p = 0.009).
The liver is the predominant site of first recurrence after resection of hepatocellular carcinoma, and once recurrence occurs survival is limited. The current study underscores the need for effective adjuvant therapy for patients with HCC treated with partial hepatectomy.
大多数接受肿瘤完全切除的肝细胞癌(HCC)患者随后会出现肿瘤复发。本研究的目的是确定肝切除术后HCC复发的危险因素,并研究肿瘤复发后的结局。
1990年2月至2001年5月,共有164例患者在我院接受了HCC肝切除术,并进行了前瞻性随访。采用Kaplan-Meier分析确定复发时间和复发后的生存率。分别使用对数秩检验和Cox比例风险模型,通过单因素和多因素分析来检验患者、肿瘤和治疗特征的预后意义。
患者的中位年龄为64岁(范围21至87岁),106例患者(65%)为男性。中位随访26个月后,90例患者(55%)出现了复发性癌症。其中,75例患者(83%)肝脏内可检测到肿瘤,这是67例(74%)患者唯一的疾病部位。共有15例患者(20%)出现肝外疾病(7例肺部、4例腹膜、2例胰腺、1例骨骼和1例脑部)。复发的中位时间为24个月(范围1至274个月)。单因素分析中复发的预测因素包括肿瘤大小大于5 cm、多个肿瘤、肝硬化、血管侵犯(显微镜下或肉眼可见)和肿瘤卫星灶。多因素分析中只有肿瘤大小大于5 cm(p = 0.04)和血管侵犯(p = 0.01)可预测复发。复发后的中位生存期为11个月(范围0至60个月)。在90例出现肿瘤复发的患者中,49例(67%)能够接受额外的消融或手术治疗(33例栓塞、9例乙醇注射和14例再次切除)。多因素分析中,原发肿瘤的血管侵犯预示着复发后生存情况较差(p = 0.009)。
肝脏是肝细胞癌切除术后首次复发的主要部位,一旦复发,生存时间有限。本研究强调了对接受部分肝切除术治疗的HCC患者进行有效辅助治疗的必要性。